OverviewSuggest Edit

Esperion Therapeutics is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated LDL-C. 

TypePublic
Founded2008
HQAnn Arbor, US
Websiteesperion.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Dec 2019)193(+154%)
Revenue (FY, 2019)$148.4 M
Share Price (Aug 2020)$38.6
Cybersecurity ratingAMore

Key People/Management at Esperion Therapeutics

Tim Mayleben

Tim Mayleben

President, CEO
Richard Bartram

Richard Bartram

CFO
Mark Glickman

Mark Glickman

Chief Commercial Officer
Ashley Hall

Ashley Hall

Chief Development Officer
Marianne Andreach

Marianne Andreach

SVP
Regina Cavaliere

Regina Cavaliere

​Chief Ethics and Compliance Officer​
Show more

Esperion Therapeutics Office Locations

Esperion Therapeutics has an office in Ann Arbor
Ann Arbor, US (HQ)
3891 Ranchero Dr
Show all (1)

Esperion Therapeutics Financials and Metrics

Esperion Therapeutics Revenue

Esperion Therapeutics's revenue was reported to be $148.36 m in FY, 2019
USD

Revenue (Q1, 2020)

1.8m

Net income (Q1, 2020)

(78.2m)

EBIT (Q1, 2020)

(74.4m)

Market capitalization (6-Aug-2020)

1.1b

Closing stock price (6-Aug-2020)

38.6

Cash (31-Mar-2020)

149.4m

EV

921.4m
Esperion Therapeutics's current market capitalization is $1.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

148.4m

General and administrative expense

18.3m21.4m33.1m65.9m

R&D expense

57.9m147.6m171.5m175.6m

Operating expense total

76.2m169.0m204.6m241.5m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

145.4m982.0k981.0k1.8m

General and administrative expense

5.0m5.4m5.7m6.0m7.0m9.0m12.2m13.5m18.5m41.6m

R&D expense

35.9m38.2m40.1m40.9m39.5m41.6m46.3m42.8m48.3m34.7m

Operating expense total

40.9m43.7m45.7m46.9m46.5m50.6m58.5m56.3m66.7m76.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

56.5m85.0m77.3m34.5m37.0m166.1m

Accounts Receivable

Prepaid Expenses

1.7m1.3m3.9m

Inventories

Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

16.6m71.9m48.6m47.9m40.2m208.6m129.8m80.8m37.2m48.8m47.1m19.9m20.4m21.0m30.8m24.4m26.8m174.8m274.3m212.0m149.4m

Prepaid Expenses

1.3m986.0k1.8m1.3m1.1m1.6m923.0k792.0k2.8m11.4m

Inventories

1.8m

Current Assets

19.4m73.0m58.3m61.3m54.6m279.8m225.7m218.8m197.1m209.1m213.5m188.0m170.9m206.8m201.4m188.9m168.2m235.2m307.1m253.5m172.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(26.1m)(36.4m)(49.8m)(75.0m)(167.0m)(201.8m)(97.2m)

Depreciation and Amortization

70.6k160.0k236.0k252.0k258.0k265.0k

Accounts Payable

1.8m(299.0k)(1.3m)3.9m15.8m24.4m(16.1m)

Cash From Operating Activities

(18.1m)(32.0m)(38.2m)(47.7m)(131.3m)(148.6m)(70.3m)
USDQ2, 2013

Financial Leverage

-0.4 x
Show all financial metrics

Esperion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Esperion Therapeutics Online and Social Media Presence

Embed Graph

Esperion Therapeutics News and Updates

Thinking about trading options or stock in Duke Energy, Esperion Therapeutics, Expedia, MSCI Inc, or Walmart?

NEW YORK, Feb. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DUK, ESPR, EXPE, MSCI, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

NEW YORK, April 24, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders....

Esperion Therapeutics Blogs

Esperion to Report First Quarter 2020 Financial Results May 6, 2020

ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and conference call at 4:30

Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020, at 12:50

Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other Lipid-Lowering Therapies, or Considered

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare Content Import Mon, 03/30/2020 - 16:15 Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pl…

Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology

Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology Content Import Sat, 03/28/2020 - 09:30 …

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol deborah.shanno… Mon, 03/23/2020 - 07:30 …
Show more

Esperion Therapeutics Frequently Asked Questions

  • When was Esperion Therapeutics founded?

    Esperion Therapeutics was founded in 2008.

  • Who are Esperion Therapeutics key executives?

    Esperion Therapeutics's key executives are Tim Mayleben, Richard Bartram and Mark Glickman.

  • How many employees does Esperion Therapeutics have?

    Esperion Therapeutics has 193 employees.

  • What is Esperion Therapeutics revenue?

    Latest Esperion Therapeutics annual revenue is $148.4 m.

  • What is Esperion Therapeutics revenue per employee?

    Latest Esperion Therapeutics revenue per employee is $768.7 k.

  • Who are Esperion Therapeutics competitors?

    Competitors of Esperion Therapeutics include Amphastar Pharmaceuticals, IntelGenx and Mylan.

  • Where is Esperion Therapeutics headquarters?

    Esperion Therapeutics headquarters is located at 3891 Ranchero Dr, Ann Arbor.

  • Where are Esperion Therapeutics offices?

    Esperion Therapeutics has an office in Ann Arbor.

  • How many offices does Esperion Therapeutics have?

    Esperion Therapeutics has 1 office.